Please assess the completion status of the following clinical trial:

Trial Title: Sedation for Patients Undergoing Endoscopic Retrograde Cholangiopancreatography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 18-65 yrs~2. ASA I \& II~Exclusion Criteria:~1. Age \< 18 yrs \& \> 65 yrs~2. ASA III \& IV patients~3. Chronic Liver Disease~4. Pregnant patients~5. Patients with a history of (H/O) Drug abuse~6. Patients refusing consent~7. H/o Acute kidney injury~8. H/o allergy to propofol / lidocaine/ NSAIDS~9. Post liver transplant patients~10. Patients with h/o egg allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: NO_INTERVENTION): The intravenous infusion of propofol was administered for ERCP procedure based on clinical judgment and the patient's requirement.
- Group B (Type: ACTIVE_COMPARATOR): The intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.
- Group C (Type: ACTIVE_COMPARATOR): Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure \& topical pharyngeal anesthesia with 4 squirts of 10% lidocaine spray ( one squirt each to posterior pharyngeal wall, base of tongue, and bilateral palatoglossal and palatopharyngeal folds ) 5 mins before the start of ERCP procedure. Intravenous infusion of propofol was administered for ERCP procedure titrated to BIS value 60-80.

Based on this trial design, predict the completion outcome and termination type (if applicable).